biotech

Pfizer BioNTech COVID-19 Vaccine Confirmed to Lower Incidence Rates in Individuals

Pfizer BioNTech COVID-19 Vaccine Confirmed to Lower Incidence Rates in Individuals

Pfizer Inc. (NYSE: PFE), The Israel Ministry of Health and BioNTech SE (NASDAQ: BNTX) reported evidence that demonstrates lower incidence rates of COVID-19 disease in individuals that are vaccinated with BNT162b2.  The new data confirms previou..

Hoth Therapeutics Shares Spike After Joint Venture for a Potential COVID-19 Vaccine

Hoth Therapeutics Shares Spike After Joint Venture for a Potential COVID-19 Vaccine

Hoth Therapeutics, Inc. (NASDAQ: HOTH) shares spiked about 90% Monday morning after the biopharmaceutical company announced that it has reached an agreement with Voltron Therapeutics, Inc. to form a joint venture entity, to be named HaloVax, which w..

BioNTech and Fosun Pharma Announced Strategic Partnership on Potential COVID-19 Vaccine

BioNTech and Fosun Pharma Announced Strategic Partnership on Potential COVID-19 Vaccine

BioNTech SE (NASDAQ: BNTX) and Shanghai Fosun Pharmaceutical (Group) Co., Ltd (“Fosun Pharma” or “Group”; Stock Symbol: 600196.SH, 02196.HK) announced today a strategic development and commercialization collaboration to advan..

Co-Diagnostics, Inc. Reports on Demand for Coronavirus Test Shipments

Co-Diagnostics, Inc. Reports on Demand for Coronavirus Test Shipments

Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced Thursday that both domestic and international demand has surged for its novel coronavirus d..

AbbVie Announces Fourth Quarter and Full Year Financials

AbbVie Announces Fourth Quarter and Full Year Financials

AbbVie Inc. (NYSE: ABBV) announced Friday financial results for the fourth quarter and full year ended December 31, 2019. Shares of the Company spiked more than 5% Friday morning.Highlights from the report include worldwide net revenues were $8..

AbbVie Inc. Announces that SKYRIZI™ Met Both Primary and All Ranked Secondary Endpoints

AbbVie Inc. Announces that SKYRIZI™ Met Both Primary and All Ranked Secondary Endpoints

AbbVie Inc. (NYSE: ABBV) announced Tuesday that SKYRIZI™ met both primary and all ranked secondary endpoints, which includes superiority at week 52, versus Cosentyx® in a head-to-head Phase 3 study. SKYRIZI showed significantly higher rate..